Home Healthcare Pharmaceuticals GLP-1 Receptor Agonist Market

GLP-1 Receptor Agonist Market Size, Share & Trends Analysis Report By Product (Semaglutide, Tirzepatide, Dulaglutide, Liraglutide, Others), By Application (Type 2 Diabetes Mellitus, Chronic Weight Management, Cardiovascular Risk Reduction, Others), By Route of Administration (Parenteral, Oral), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: July 17, 2026 | Author: Pavan Warade | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. GLP-1 Receptor Agonist Market, By Product 2022-2034 (USD MILLION/ Units)
    1. Semaglutide 
    2. Tirzepatide 
    3. Dulaglutide 
    4. Liraglutide 
    5. Others
  2. GLP-1 Receptor Agonist Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Type 2 Diabetes Mellitus
    2. Chronic Weight Management
    3. Cardiovascular Risk Reduction
    4. Others
  3. GLP-1 Receptor Agonist Market, By Route of Administration 2022-2034 (USD MILLION/ Units)
    1. Parenteral
    2. Oral
  4. GLP-1 Receptor Agonist Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. Online Pharmacies
  5. Regional GLP-1 Receptor Agonist Market
    1. North America
      1. North America GLP-1 Receptor Agonist Market By Product 2022-2034 (USD MILLION/ Units)
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
      2. North America GLP-1 Receptor Agonist Market By Application 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes Mellitus
        2. Chronic Weight Management
        3. Cardiovascular Risk Reduction
        4. Others
      3. North America GLP-1 Receptor Agonist Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral
        2. Oral
      4. North America GLP-1 Receptor Agonist Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      5. U.S.
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      6. Canada
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
    2. Europe
      1. Europe GLP-1 Receptor Agonist Market By Product 2022-2034 (USD MILLION/ Units)
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
      2. Europe GLP-1 Receptor Agonist Market By Application 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes Mellitus
        2. Chronic Weight Management
        3. Cardiovascular Risk Reduction
        4. Others
      3. Europe GLP-1 Receptor Agonist Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral
        2. Oral
      4. Europe GLP-1 Receptor Agonist Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      5. U.K.
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      6. Germany
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      7. France
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      8. Spain
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      9. Italy
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      10. Russia
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      11. Nordic
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      12. Benelux
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      13. Rest of Europe
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
    3. APAC
      1. APAC GLP-1 Receptor Agonist Market By Product 2022-2034 (USD MILLION/ Units)
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
      2. APAC GLP-1 Receptor Agonist Market By Application 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes Mellitus
        2. Chronic Weight Management
        3. Cardiovascular Risk Reduction
        4. Others
      3. APAC GLP-1 Receptor Agonist Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral
        2. Oral
      4. APAC GLP-1 Receptor Agonist Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      5. China
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      6. Korea
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      7. Japan
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      8. India
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      9. Australia
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      10. Taiwan
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      11. South East Asia
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      12. Rest of Asia-Pacific
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
    4. Middle East and Africa
      1. Middle East and Africa GLP-1 Receptor Agonist Market By Product 2022-2034 (USD MILLION/ Units)
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
      2. Middle East and Africa GLP-1 Receptor Agonist Market By Application 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes Mellitus
        2. Chronic Weight Management
        3. Cardiovascular Risk Reduction
        4. Others
      3. Middle East and Africa GLP-1 Receptor Agonist Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral
        2. Oral
      4. Middle East and Africa GLP-1 Receptor Agonist Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      5. UAE
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      6. Turkey
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      7. Saudi Arabia
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      8. South Africa
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      9. Egypt
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      10. Nigeria
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      11. Rest of MEA
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
    5. LATAM
      1. LATAM GLP-1 Receptor Agonist Market By Product 2022-2034 (USD MILLION/ Units)
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
      2. LATAM GLP-1 Receptor Agonist Market By Application 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes Mellitus
        2. Chronic Weight Management
        3. Cardiovascular Risk Reduction
        4. Others
      3. LATAM GLP-1 Receptor Agonist Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral
        2. Oral
      4. LATAM GLP-1 Receptor Agonist Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      5. Brazil
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      6. Mexico
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      7. Argentina
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      8. Chile
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      9. Colombia
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      10. Rest of LATAM
        1. Semaglutide 
        2. Tirzepatide 
        3. Dulaglutide 
        4. Liraglutide 
        5. Others
        6. Type 2 Diabetes Mellitus
        7. Chronic Weight Management
        8. Cardiovascular Risk Reduction
        9. Others
        10. Parenteral
        11. Oral
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.